--- title: "Director Sells 50,000 Shares of Digital Health Platform Stock for $1.9 Million, According to Recent SEC Filing" type: "News" locale: "en" url: "https://longbridge.com/en/news/281774964.md" description: "On April 1, 2026, Gabriel M.I. Mecklenburg, Director at Hinge Health, sold 50,000 Class A shares for approximately $1.92 million, reducing his direct holdings to zero. The shares were sold at a weighted average price of $38.46, aligning closely with the market close of $38.49. This transaction was part of a Rule 10b5-1 trading plan. Hinge Health has seen a 23% increase in stock value over the past year, despite a 15% decline year-to-date, and reported a 46% year-over-year revenue increase in Q4 2026." datetime: "2026-04-06T15:20:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281774964.md) - [en](https://longbridge.com/en/news/281774964.md) - [zh-HK](https://longbridge.com/zh-HK/news/281774964.md) --- # Director Sells 50,000 Shares of Digital Health Platform Stock for $1.9 Million, According to Recent SEC Filing ## Key Points - 50,000 Class A shares were sold on April 1, 2026, with a transaction value of ~$1.92 million based on a weighted average price of $38.46 per share. - This disposition represented 100.00% of Mecklenburg's direct Class A Common Stock holdings at the time, reducing his direct Class A position to zero. - All shares sold were held directly and originated from the conversion of derivative securities; no indirect entities participated in this transaction. - 10 stocks we like better than Hinge Health › On April 1, 2026, Gabriel M.I. Mecklenburg, Director at **Hinge Health** (NYSE:HNGE), executed the sale of 50,000 Class A Common Stock shares for a total consideration of approximately $1.92 million, according to the SEC Form 4 filing. ## Transaction summary Metric Value Shares sold (direct) 50,000 Transaction value $1.9 million Post-transaction shares (direct) 0 Post-transaction value (direct ownership) ~$0 _Transaction value based on SEC Form 4 weighted average purchase price ($38.46); post-transaction value based on April 1, 2026 market close ($38.49)._ ## Key questions - **What is the derivative context for this sale?** The 50,000 Class A shares sold originated from the conversion of derivative securities, with the conversion occurring immediately prior to sale, aligning with common liquidity practices among equity holders with substantial vested options. - **How does this transaction affect Mecklenburg's ownership in Hinge Health?** The sale reduced Mecklenburg's direct Class A Common Stock holdings to zero, but he continues to hold 3,268,813 Class B Common Stock shares (direct and indirect), which are fully convertible to Class A shares, supporting ongoing beneficial ownership. - **Is this transaction part of a routine plan or discretionary action?** This transaction is part of a Rule 10b5-1 trading plan adopted by Mecklenburg on Dec. 1, 2025. - **What is the context for transaction pricing relative to market levels?** The weighted average sale price of around $38.46 per share was in line with the April 1, 2026 market close of $38.49, suggesting no price concession for liquidity and reflecting normal market execution for volume at this scale. ## Company overview Metric Value Price (as of market close 2026-04-01) $38.46 Market capitalization $3.07 billion Revenue (TTM) $587.86 million Net income (TTM) \-$528.26 million \* 1-year performance is calculated using April 1st, 2026 as the reference date. ## Company snapshot - Delivers digital healthcare solutions for musculoskeletal conditions, including joint and muscle health, acute injury, chronic pain, and post-surgical rehabilitation. - Operates a software-driven platform that provides care management and support services for musculoskeletal conditions. Hinge Health, Inc. is a healthcare technology company specializing in digital musculoskeletal care, leveraging a scalable software platform to address complex joint and muscle conditions. ## What this transaction means for investors Hinge Health stock has been on a rollercoaster of late. Over the last 12 months, shares soared by as much as 80%, before pulling back. Overall, shares have advanced by 23% over the last year. However, they have declined by 15% year to date, driven by broader market weakness. The company, which operates in the health technology industry, reported solid fourth-quarter results in February 2026. Revenue increased by 46% year-over-year to $171 million, while free cash flow was $62 million, a 65% year-over-year increase. As a growth stock, Hinge remains focused on expanding its customer base and revenue. Total customers increased 25% to more than 2,800. Turning to valuation, Hinge is looking more attractive, as its price-to-sales (P/S) ratio declines as revenue grows. For example, Hinge’s current P/S ratio stands at 5.4x, down from more than 10x in September 2025. For growth-oriented investors interested in the health technology sector, Hinge Health is a stock to keep an eye on. ## Should you buy stock in Hinge Health right now? Before you buy stock in Hinge Health, consider this: The _Motley Fool Stock Advisor_ analyst team just identified what they believe are the **10 best stocks** for investors to buy now… and Hinge Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when **Netflix** made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, **you’d have $532,066**!\* Or when **Nvidia** made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, **you’d have $1,087,496**!\* Now, it’s worth noting _Stock Advisor’s_ total average return is 926% — a market-crushing outperformance compared to 185% for the S&P 500. **Don't miss the latest top 10 list, available with _Stock Advisor_, and join an investing community built by individual investors for individual investors.** See the 10 stocks » _\*Stock Advisor returns as of April 6, 2026._ _Jake Lerch has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy._ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ### Related Stocks - [XHS.US](https://longbridge.com/en/quote/XHS.US.md) - [XHE.US](https://longbridge.com/en/quote/XHE.US.md) - [IHI.US](https://longbridge.com/en/quote/IHI.US.md) - [HNGE.US](https://longbridge.com/en/quote/HNGE.US.md) - [IHF.US](https://longbridge.com/en/quote/IHF.US.md) ## Related News & Research - [Insider Selling: Hinge Health (NYSE:HNGE) Chairman Sells 33,333 Shares of Stock](https://longbridge.com/en/news/283725496.md) - [Hinge Health launches comprehensive Migraine Care Program | HNGE Stock News](https://longbridge.com/en/news/284592937.md) - [CoreWeave Insider Sold Shares Worth $31,346,733, According to a Recent SEC Filing](https://longbridge.com/en/news/284716257.md) - [Symbotic Insiders Sold Shares Worth Over $3.4M](https://longbridge.com/en/news/284280301.md) - [Suja Life launches IPO roadshow, targets $21–$24 per share](https://longbridge.com/en/news/284210193.md)